Free Trial

Allogene Therapeutics (ALLO) Competitors

$2.35
-0.19 (-7.48%)
(As of 06/14/2024 ET)

ALLO vs. FATE, BLUE, SANA, VIR, BCRX, CGEM, TARS, FDMT, DNA, and IMTX

Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Fate Therapeutics (FATE), bluebird bio (BLUE), Sana Biotechnology (SANA), Vir Biotechnology (VIR), BioCryst Pharmaceuticals (BCRX), Cullinan Therapeutics (CGEM), Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), Ginkgo Bioworks (DNA), and Immatics (IMTX). These companies are all part of the "biological products, except diagnostic" industry.

Allogene Therapeutics vs.

Allogene Therapeutics (NASDAQ:ALLO) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, community ranking, earnings, valuation, institutional ownership and media sentiment.

Allogene Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 5.0% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fate Therapeutics has higher revenue and earnings than Allogene Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene Therapeutics$90K5,457.22-$327.27M-$1.79-1.31
Fate Therapeutics$63.53M6.50-$160.93M-$1.92-1.89

In the previous week, Fate Therapeutics had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for Fate Therapeutics and 4 mentions for Allogene Therapeutics. Fate Therapeutics' average media sentiment score of 0.91 beat Allogene Therapeutics' score of 0.90 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allogene Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fate Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Allogene Therapeutics currently has a consensus price target of $9.95, suggesting a potential upside of 312.86%. Fate Therapeutics has a consensus price target of $6.58, suggesting a potential upside of 79.87%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Fate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allogene Therapeutics
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70
Fate Therapeutics
1 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14

Fate Therapeutics received 208 more outperform votes than Allogene Therapeutics when rated by MarketBeat users. Likewise, 68.62% of users gave Fate Therapeutics an outperform vote while only 64.83% of users gave Allogene Therapeutics an outperform vote.

CompanyUnderperformOutperform
Allogene TherapeuticsOutperform Votes
271
64.83%
Underperform Votes
147
35.17%
Fate TherapeuticsOutperform Votes
479
68.62%
Underperform Votes
219
31.38%

Fate Therapeutics has a net margin of -2,933.79% compared to Allogene Therapeutics' net margin of -223,139.98%. Fate Therapeutics' return on equity of -46.49% beat Allogene Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Allogene Therapeutics-223,139.98% -50.81% -40.82%
Fate Therapeutics -2,933.79%-46.49%-34.48%

Summary

Fate Therapeutics beats Allogene Therapeutics on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALLO vs. The Competition

MetricAllogene TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$491.15M$2.85B$5.14B$8.40B
Dividend YieldN/A2.28%2.82%4.04%
P/E Ratio-1.3113.13136.8715.51
Price / Sales5,457.22301.682,166.0971.02
Price / CashN/A158.2234.0831.32
Price / Book0.773.864.834.22
Net Income-$327.27M-$45.13M$110.17M$216.08M
7 Day Performance1.29%-1.47%-0.10%-0.40%
1 Month Performance-20.61%-5.68%-1.50%-1.96%
1 Year Performance-52.86%-3.86%-0.74%1.94%

Allogene Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FATE
Fate Therapeutics
4.2506 of 5 stars
$3.62
-1.6%
$6.58
+81.9%
-32.3%$412.07M$63.53M-1.89181Short Interest ↑
BLUE
bluebird bio
2.3003 of 5 stars
$0.91
+0.9%
$5.46
+498.1%
-73.0%$99.86M$3.60M-1.23323Short Interest ↓
Positive News
SANA
Sana Biotechnology
2.0775 of 5 stars
$6.95
-0.4%
$11.67
+67.9%
+11.4%$1.54BN/A-4.54328Positive News
VIR
Vir Biotechnology
2.2969 of 5 stars
$10.86
-3.3%
$34.14
+214.4%
-61.2%$1.48B$86.18M-2.71587Gap Down
BCRX
BioCryst Pharmaceuticals
4.1552 of 5 stars
$6.35
+0.6%
$14.00
+120.5%
-23.8%$1.31B$331.41M-5.93536Short Interest ↑
Positive News
CGEM
Cullinan Therapeutics
2.0806 of 5 stars
$22.73
+1.5%
$32.00
+40.8%
+78.8%$1.31B$18.94M-7.2685Short Interest ↑
TARS
Tarsus Pharmaceuticals
1.4242 of 5 stars
$32.28
+0.2%
$50.38
+56.1%
+74.9%$1.22B$17.45M-6.77244Positive News
FDMT
4D Molecular Therapeutics
2.3182 of 5 stars
$22.42
-1.3%
$45.63
+103.5%
+4.9%$1.16B$20.72M-9.19147
DNA
Ginkgo Bioworks
2.3348 of 5 stars
$0.51
-1.6%
$1.90
+275.5%
-76.1%$1.12B$251.46M-1.151,218Short Interest ↓
IMTX
Immatics
0.5286 of 5 stars
$13.08
-0.6%
$16.00
+22.3%
+7.6%$1.11B$58.44M-12.34432Short Interest ↑
Positive News
High Trading Volume

Related Companies and Tools

This page (NASDAQ:ALLO) was last updated on 6/14/2024 by MarketBeat.com Staff

From Our Partners